AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01567631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classical hepatectomy
Description: Forty patients with liver disease were selected and divided into classical laparoscopic hepatectomy group as described in the detailed description.Total laparoscopic anatomical hepatectomy with classical procedure were performed.The initial step is to dissect hepatic portal and expose the liver artery, portal Vein branch and the bile duct. Then endoscopic stapler devices were used to cut the canal mentioned above. Final step is to divide the liver parenchyma along the following ischemic delineation.
Study NCT03430947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib (960 mg twice a day) will be taken on days 1 - 28 of each 28-day treatment cycle.
Study NCT03430947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib (60 mg once a day) will be taken on days 1 - 21 of each 28-day treatment cycle.
Study NCT01773083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unfractionated heparin
Description: nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days
Study NCT01773083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days
Study NCT05119127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon Vivity toric intra ocular lens
Description: implanting vivity toric IOL to asses rotational stability. IOL is already FDA approved for implantation at time of cataract surger. Intervention is to assess rotational stability and visual outcome.
Study NCT03463629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized multidisciplinary diabetes team (SMDT) approach
Description: The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor.
Study NCT03578653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Merging Yoga and Occupational Therapy for Parkinson disease
Description: The group occupational therapy portion focuses on lecture, group discussion, and activities to reduce fall risk. The yoga program is part of an ongoing community yoga program specifically designed for people with Parkinson disease.
Study NCT03163927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Description: See arm description
Study NCT01365481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily
Study NCT01365481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Description: added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
Study NCT01365481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
Study NCT00472849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 30 mg/m\^2/day, over approximately 2 hours, before fludarabine is started, on days 1-4.
Study NCT00472849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m\^2 daily IV, over approximately 30 minutes, on days 2-3, 2-4, or 2-5 until maximum tolerated dose is reached.
Study NCT00472849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 500 mg/m\^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.
Study NCT00472849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 IV on day 3, course 1 (on day 1, subsequent courses).
Study NCT00472849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy
Study NCT03364075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 30 mg for seven days, then increased to 60 mg for seven days
Study NCT03364075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: 30 mg for seven days, then increased to 60 mg for seven days
Study NCT03364075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: 40 mg for seven days, then increase to 60 mg for seven days
Study NCT03364075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 40 mg for seven days, then increase to 60 mg for seven days
Study NCT03364075 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genotype for SNPs associated to Serotonin and COMT
Description: DNA and RNA extraction from blood samples to identify genetic variants associated to pain pathways
Study NCT03364075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Treatment
Description: 1 capsule BID for two weeks
Study NCT03463629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional model of care
Description: Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services
Study NCT00955500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched-chain amino acids
Description: 30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily
Study NCT02915419 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: platelet rich plasma
Study NCT02915419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: platelet rich plasma
Study NCT02915419 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRF
Description: PLATELET RICH FIBRIN
Study NCT02915419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF
Description: PLATELET RICH FIBRIN
Study NCT00955500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin
Description: 30 grams of oral maltodextrin daily
Study NCT01546051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-838
Description: BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design
Study NCT02261753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Classical ketogenic diet
Description: A high fat low carbohydrate, low protein diet.
Study NCT01546051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-838
Description: BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design
Study NCT01344772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal fixation
Description: Two cannulated screws are placed under x-ray guidance
Study NCT01546051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-1038, BCI-1206 & BCI-1283
Description: Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
Study NCT01344772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: A total hip arthroplasty is performed through a standard posterior approach
Study NCT01274325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sereflo
Description: Patients take sereflo (25/125) 2 puffs twice a day for 4 weeks
Study NCT01274325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: Patients will take Seretide (25/125) 2 puffs twice a day for 4 weeks
Study NCT03913572 — intervention group
Intervention type: PROCEDURE
Intervention: Injection of adipose-derived stem cells into perianal fistula
Description: The plastic surgery team will perform fat graft harvest. Tumescent solution will be infiltrated into the area of liposuction, generally the abdomen, flanks, or thighs. Approximately a00ml of liposuction aspirate will be retrieved. It will be washed and condensed down to about 5-25 ml of good-quality fat graft using the REVOLVE System by Acelity. This will then be loaded into a syringe fitted with an injection cannula. The colorectal surgeon will perform an exam under anesthesia and determine if any additional procedure such as ligation of fistula tract, fistulotomy, endorectal advancement flap, or seton placement/exchange is needed. Severity of disease at time of surgery will be recorded by the attending surgeon. Following any indicated procedure, the lipoaspirate will be injected into the soft tissues around the fistula tract.
Study NCT05012553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education of self and peer assesment
Description: Stoma care skill achievement is expected to be higher in the group that received self- and peer-assessment training compared to the group that did not receive training.
Study NCT01546051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-838
Description: BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions
Study NCT02976610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemolysis Point-of-Care test
Description: Hemolysis measurement of plasma using a point of care test to determine the hemolysis level in plasma
Study NCT02745652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed electromagnetic field
Description: it is a magnetic device for magneto-therapy, it has an appliance, motorized bed, and applicable large solenoids which can be moved in 4 different positions according to the treatment area, and the additional small solenoid for hand treatment with 30 cm diameter
Study NCT02745652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: Ultrasound is applied using a transducer or applicator that is in direct contact with the patient's skin. Gel is a medium which is used on all surfaces of the head to reduce friction and assist transmission of the ultrasonic waves
Study NCT04179877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPS
Description: Occupational rehabilitation and support Integrated with clinical treatment
Study NCT02029131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Educated exercise training for the trunk 3 times per week, each for 20 min. Recommendation of additional fitness courses as offered by the local healthy insurance company.
Study NCT00680329 — intervention group
Intervention type: DRUG
Intervention: Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)
Description: One drop in study eye(s) once daily in the evening for four months
Study NCT00680329 — intervention group
Intervention type: DEVICE
Intervention: Travalert Dosing Aid
Description: Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
Study NCT01914237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Castor Stent Graft
Description: Endovascular Repair of Aortic Dissection
Study NCT03319433 — intervention group
Intervention type: DEVICE
Intervention: Perfusion Index
Description: Use of non-invasive pulse oximeter to determine perfusion index
Study NCT00318721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Lasting Impregnated Nets (LLIN)
Description: Distribution of LLIN in selected clusters
Study NCT00318721 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Long Lasting Impregnated Nets (LLIN)
Description: Distribution of LLIN in selected clusters
Study NCT01585077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected mosquito bites
Description: All volunteers will receive one dose of 2-4 P. vivax infected mosquito bites. All the mosquitoes will correspond to the same mosquito batch to make sure that all volunteers receive the same P. vivax strain.
Study NCT02663531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DVA
Study NCT02663531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDOCT
Study NCT02663531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pattern ERG
Study NCT02663531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Study NCT04223986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: decide between the need for intervention or not (Percutaneous coronary intervention)
Study NCT04223986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Troponin- T quick test
Description: Quick test for Troponin T blood assessment
Study NCT01641159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
Study NCT01641159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.
Study NCT03653208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
Study NCT02515903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-endoscopic surgery
Description: Intra-endoscopic surgery for evacuation of ICH
Study NCT03653208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1 (single administration)
Study NCT01529320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adventan® (methylprednisolone aceponate 0,1%)
Description: Doses: 1/4 FTU (Finger Tip Unit) during 5 days (Day 7-Day 11). Procedure: Patch Test (Nickel sulphate 5%) during 2 days (Day 0- Day 2.
Study NCT00436605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Study NCT03934177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry powder
Description: Dried, powdered blueberries will be consumed at 24 g/day in two divided doses at least 4 hours apart.
Study NCT03934177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: A placebo consisting maltodextrin will be consumed at 24 g/day in two divided doses at least 4 hours apart.
Study NCT03417570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)
Description: -The second endoscopist will be blinded to the results of the initial exam.
Study NCT03417570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Disposable Distal Attachment Cap
Description: -The second endoscopist will be blinded to the results of the initial exam.
Study NCT01409629 — intervention group
Intervention type: BEHAVIORAL
Intervention: Computer game
Description: Participants will play a computer game
Study NCT01696045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02736240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine
Study NCT02736240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal polysaccharide conjugate vaccine
Study NCT02416960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Diet Group
Description: This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, low glycemic index/load diet.
Study NCT02416960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diet Group
Description: This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, high glycemic index/load diet.
Study NCT04479228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endosonography guided transmural drainage
Description: The procedures would be performed by experienced endoscopists. All procedures will be performed with the patient in the left lateral position under propofol sedation after administration of intravenous antibiotics (third generation cephalosporins) A therapeutic linear echo-endoscope (UCT-180; Olympus Ltd, Tokyo, Japan) will be used; the PFC assessed for size, wall maturity, thickness, interposing collaterals and percentage of solid debris
Study NCT02158923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Description: To start Alveolar Recruitment Maneuver (ARM), change ventilatory pressure-controlled mode (PCV) with 15 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 10 cmH2O. PEEP level will increase 5 on 5 cmH2O every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (25 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
Study NCT02158923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calculation of optimal PEEP
Description: Change ventilation mode to volume controlled ventilation (VCV) with a VT of 8 ml / kg, RR 15 rpm and adjust a PEEP of 20 cmH2O. Descend PEEP level 2 by 2 cmH2O every 30 seconds until obtain the best respiratory system compliance (Crs) PEEP. Once you know the optimal level of PEEP (best Crs PEEP), will be conducted again alveolar recruitment maneuver and adjust the best Crs level of PEEP + 2 cmH2O .
Study NCT02158923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative CPAP
Description: Postoperatively, non-invasive mechanical ventilation with a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
Study NCT02158923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative CPAP
Description: Postoperatively, non-invasive mechanical ventilation with a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
Study NCT01986764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine
Study NCT01986764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Study NCT01986764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be filled with lactose powder.
Study NCT04549649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual triggering
Description: Adding GnRH agonist (0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) to routine oocyte triggering (two ampoules of Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) is defined as dual triggering.
Study NCT03260777 — intervention group
Intervention type: DEVICE
Intervention: Trichoscopy
Description: Trichoscopy (hair and scalp dermoscopy) is a noninvasive diagnostic tool that allows the recognition of morphologic structures not visible by the naked eye Structures which may be visualized by trichoscopy include hair shafts of different types, the number of hairs in one pilosebaceous unit, hair follicle openings (dots), the peri and interfollicular areas and the vasculature.
Study NCT03284203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpiroPD
Description: At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal.
Study NCT03170687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: short foot cast
Description: metatarsal foot cast
Study NCT03170687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: short leg cast
Description: full short leg cast
Study NCT03541200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554
Description: MT-8554 Oral
Study NCT04237532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine
Description: The mucosal atomizing device will be used intranasally where the sedative drug will be equally divided and sprayed into each nostril while the child semi reclined position.
Study NCT04237532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Dexmedetomidine
Description: The mucosal atomizing device will be used sublingually by asking the child to touch their maxillary incisor teeth with the tip of their tongue and instruct the child not to swallow the drug for 30 seconds.